口咽癌长期生存者发声与言语症状的风险因素分析
这项回顾性队列研究纳入2000至2013年在MD Anderson癌症中心接受根治性治疗的无癌口咽癌生存者,于2015至2016年进行横断面调查,分析881例患者报告的发声与言语评分。结果显示12.8%报告中度至重度症状,生存时间延长、总放疗剂量增加、黑人种族、西班牙裔、当前吸烟、诱导联合同步化疗、晚期及基线低位颅神经病变为风险因素,调强放疗分野方案与较低风险相关。
要点
- 口咽癌长期生存者中12.8%报告中度至重度发声与言语症状。
- 当前吸烟、晚期低位颅神经病变及诱导联合同步化疗显著增加症状风险。
- 调强放疗分野方案与较低的中度至重度发声言语症状风险相关。
核心结论
- 口咽癌长期生存者中,多种治疗相关、临床和人口学因素与中度至重度发声与言语症状相关。
- 调强放疗分野方案与较低的中度至重度发声言语症状风险相关。
- 生存时间较长者和持续吸烟者发声与言语症状更差。
研究设计与样本
- 回顾性队列研究结合横断面生存者调查,纳入2000年1月至2013年12月在MD Anderson癌症中心接受根治性治疗的无癌口咽癌生存者。
- 906例生存者中位生存时间6年(范围1-16年),其中881例患者报告的发声与言语结局可获取并纳入分析。
- 调查于2015年9月至2016年7月进行,数据分析时间为2020年6月30日至2021年2月28日。
主要发现
- 881例生存者中,113例(12.8%)报告中度至重度发声与言语评分。
- 生存时间延长(OR 1.17;95%CI 1.06-1.30)和总放疗剂量增加(OR 1.16;95%CI 1.00-1.34)与中度至重度症状相关。
- 黑人种族(OR 3.90;95%CI 1.02-14.89)、西班牙裔(OR 3.74;95%CI 1.50-9.35)、调查时当前吸烟(OR 3.98;95%CI 1.56-10.18)与中度至重度症状相关。
- 诱导联合同步化疗(OR 1.94;95%CI 1.06-3.57)、晚期低位颅神经病变(OR 7.11;95%CI 3.08-16.41)和基线低位颅神经病变(OR 8.70;95%CI 3.01-25.13)与中度至重度症状相关。
关键数值与推荐
- 发声与言语评分采用MD Anderson症状量表-头颈癌模块测量,0-4分归类为无至轻度症状,5-10分归类为中度至重度症状。
- 风险因素通过多变量逻辑回归识别。
临床怎么用
- 对口咽癌生存者应关注发声与言语症状,尤其存在高放疗剂量、诱导联合同步化疗、持续吸烟及低位颅神经病变者。
- 调强放疗分野方案可能有助于降低发声与言语症状风险,临床决策时可考虑。
- 持续吸烟与更差的发声言语症状相关,应加强戒烟干预以保护发声与言语功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Voice and speech production are critical physiological functions that affect quality of life and may deteriorate substantially after oropharyngeal cancer (OPC) treatment. There is limited knowledge about risk factors associated with voice and speech outcomes among survivors of OPC. OBJECTIVE: To identify the risk factors of voice and speech symptoms among long-term survivors of OPC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study with cross-sectional survivorship survey administration includes cancer-free survivors of OPC who were treated curatively between January 2000 and December 2013 at MD Anderson Cancer Center (Houston, Texas) who participated in a survey from September 2015 to July 2016. Of 906 survivors of OPC with a median survival duration at time of survey of 6 years (range, 1-16 years), patient-rated voice and speech outcomes for 881 were available and analyzed. The data were analyzed from June 30, 2020, to February 28, 2021. MAIN OUTCOMES AND MEASURES: The primary outcome variable was patient-reported voice and speech scores that were measured using the MD Anderson Symptom Inventory-Head and Neck Cancer Module. Voice and speech scores of 0 to 4 were categorized as none to mild symptoms, and scores of 5 to 10 were categorized as moderate to severe symptoms. Risk factors for moderate to severe voice and speech symptoms were identified by multivariable logistic regression. RESULTS: Among 881 survivors of OPC (median [range] age, 56 [32-84] years; 140 women [15.5%]; 837 White [92.4%], 17 Black [1.9%], and 35 Hispanic individuals [3.8%]), 113 (12.8%) reported moderate to severe voice and speech scores. Increasing survival time (odds ratio [OR], 1.17; 95% CI, 1.06-1.30) and increasing total radiation dose (OR, 1.16; 95% CI, 1.00-1.34), Black race (OR, 3.90; 95% CI, 1.02-14.89), Hispanic ethnicity (OR, 3.74; 95% CI, 1.50-9.35), current cigarette smoking at the time of survey (OR, 3.98; 95% CI, 1.56-10.18), treatment with induction and concurrent chemotherapy (OR, 1.94; 95% CI, 1.06-3.57), and late (OR, 7.11; 95% CI, 3.08-16.41) and baseline lower cranial neuropathy (OR, 8.70; 95% CI, 3.01-25.13) were risk factors associated with moderate to severe voice and speech symptoms. Intensity-modulated radiotherapy split-field regimen (OR, 0.31; 95% CI, 0.12-0.80; P = .01) was associated with lower likelihood of moderate to severe voice and speech symptoms. CONCLUSIONS AND RELEVANCE: This large OPC survivorship cohort study identified many treatment-related factors, including increasing total radiotherapy dose, multimodality induction and concurrent chemotherapy regimens, and continued smoking, as well as clinical and demographic factors, as risk factors that were associated with moderate to severe voice and speech symptoms. The key findings in this study were the protective associations of split-field radiation and that longer-term survivors, and those who continued to smoke, had worse voice and speech symptoms. These findings may inform research and effective targeted clinical voice and speech preservation interventions and smoking cessation interventions to maximize voice and speech function and address quality of life among patients with OPC.
引用
- Aggarwal P, Hutcheson KA, Garden AS, et al. Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33956062. doi:10.1001/jamaoto.2021.0698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。